Larry Zeitlin
About Larry Zeitlin
Larry Zeitlin is a researcher and President who has co-authored significant studies on viral therapies and prophylaxis in nonhuman primates.
Larry Zeitlin President
Larry Zeitlin holds the position of President. His role encompasses the leadership and strategic direction of the organization. His responsibilities likely include overseeing daily operations, guiding the company’s vision, and making significant corporate decisions. Larry Zeitlin’s leadership role suggests an extensive background in management and a measured approach to navigating the business landscape.
Larry Zeitlin Research on Marburg Virus
Larry Zeitlin co-authored research on long-term prophylaxis against the aerosolized Marburg virus in nonhuman primates. This study focused on the use of an afucosylated monoclonal antibody to provide prevention. The research provided valuable insights into potential protective measures against the virus, contributing to the field of infectious disease prevention and treatment.
Larry Zeitlin Research on Argentine Hemorrhagic Fever
Larry Zeitlin co-authored research on therapy for Argentine hemorrhagic fever in nonhuman primates utilizing a humanized monoclonal antibody. This work aimed to explore treatment options for the disease, showcasing the antibody's therapeutic potential. The findings are relevant for advancing medical approaches and treatment protocols for hemorrhagic fevers.
Larry Zeitlin Research on Nipah Virus
Larry Zeitlin participated in research on the therapeutic administration of a cross-reactive monoclonal antibody targeting the fusion glycoprotein of the Nipah virus. This study demonstrated the protective benefits for nonhuman primates. The research significantly contributes to the understanding of Nipah virus treatment, providing a basis for future therapeutic developments.